Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
ZIOPHARM Oncology, Inc is a biotechnology business based in the US. ZIOPHARM Oncology shares (ZIOP) are listed on the NASDAQ and all prices are listed in US Dollars. ZIOPHARM Oncology employs 73 staff and has a market cap (total outstanding shares value) of USD$605.4 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$2.74 |
---|---|
52-week range | USD$1.795 - USD$5.605 |
50-day moving average | USD$2.5489 |
200-day moving average | USD$2.8916 |
Wall St. target price | USD$5.93 |
PE ratio | 4.3467 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$0.575 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.74 from 2020-12-09
1 week (2021-01-05) | -3.52% |
---|---|
1 month (2020-12-12) | N/A |
3 months (2020-10-12) | -1.97% |
6 months (2020-07-12) | N/A |
1 year (2020-01-12) | N/A |
---|---|
2 years (2019-01-12) | N/A |
3 years (2018-01-12) | 4.36 |
5 years (2016-01-12) | 6.27 |
Valuing ZIOPHARM Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ZIOPHARM Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ZIOPHARM Oncology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, ZIOPHARM Oncology shares trade at around 4x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Gross profit TTM | USD$-38,331,000 |
---|---|
Return on assets TTM | -32.42% |
Return on equity TTM | -58.12% |
Profit margin | 0% |
Book value | $0.681 |
Market capitalisation | USD$605.4 million |
TTM: trailing 12 months
There are currently 33.4 million ZIOPHARM Oncology shares held short by investors – that's known as ZIOPHARM Oncology's "short interest". This figure is 0.1% down from 33.5 million last month.
There are a few different ways that this level of interest in shorting ZIOPHARM Oncology shares can be evaluated.
ZIOPHARM Oncology's "short interest ratio" (SIR) is the quantity of ZIOPHARM Oncology shares currently shorted divided by the average quantity of ZIOPHARM Oncology shares traded daily (recently around 1.5 million). ZIOPHARM Oncology's SIR currently stands at 22.32. In other words for every 100,000 ZIOPHARM Oncology shares traded daily on the market, roughly 22320 shares are currently held short.
However ZIOPHARM Oncology's short interest can also be evaluated against the total number of ZIOPHARM Oncology shares, or, against the total number of tradable ZIOPHARM Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ZIOPHARM Oncology's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 ZIOPHARM Oncology shares in existence, roughly 160 shares are currently held short) or 0.1699% of the tradable shares (for every 100,000 tradable ZIOPHARM Oncology shares, roughly 170 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against ZIOPHARM Oncology.
Find out more about how you can short ZIOPHARM Oncology stock.
We're not expecting ZIOPHARM Oncology to pay a dividend over the next 12 months.
ZIOPHARM Oncology's shares were split on a 1:40 basis on 24 August 2005. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ZIOPHARM Oncology shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for ZIOPHARM Oncology shares which in turn could have impacted ZIOPHARM Oncology's share price.
Over the last 12 months, ZIOPHARM Oncology's shares have ranged in value from as little as $1.795 up to $5.605. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ZIOPHARM Oncology's is 2.2356. This would suggest that ZIOPHARM Oncology's shares are significantly more volatile than the average for this exchange and represent a higher risk.
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. It is developing Ad-RTS-hIL-12 plus veledimex, which is in Phase 2 clinical trial, to treat patients with recurrent glioblastoma multiforme in adults. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; collaboration with MD Anderson targeting CD19 on malignant B cells using Sleeping Beauty platform; and research and development agreement with the National Cancer Institute to evaluate autologous peripheral blood lymphocytes, and Ares Trading S.A. The company was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.